Toggle Main Menu Toggle Search

Open Access padlockePrints

Multivalent targeting and killing of HER2 overexpressing breast carcinoma cells with methotrexate-encapsulated tetra-specific non-overlapping variable domain heavy chain anti-HER2 antibody-PEG-liposomes: In vitro proof-of-concept

Lookup NU author(s): Professor Moein MoghimiORCiD


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


© 2018 Elsevier B.V. The variable domain of the heavy chain antibodies (VHHs) is the smallest (15 kDa) intact single domain antigen-binding fragment. VHHs often exhibit sub-nanomolar affinity for their designated targets and therefore are receiving increasing attention in molecular targeting and nanomedicine engineering. We cloned and expressed four non-overlapping anti-HER2 VHHs in a prokaryotic expression system that yielded disulfide-bonded VHHs. Purified VHHs, before and after thiolation, were characterized by Western blot and their functionality against the ecto-domain of HER2 receptor was confirmed by ELISA and flow cytometry. Thiolated VHHs were conjugated to the reactive maleimide-PEG2000-distearoylphosphatidylethanolamine incorporated into the bilayer of small unilamellar vesicles. We show high target-binding avidity and efficient cytotoxicity of optimized tetra-specific multivalent methatoraxate-loaded VHH-PEG-liposomes (55–60 VHH/vesicle) in HER2 over-expressing breast carcinoma cell lines compared with the best performing monoclonal VHH conjugated vesicles of identical VHH surface density. The VHH expression and production methodology as well as the synergistic effect of the four non-overlapping VHHs in HER2 binding provides an efficient approach for design and engineering of anti-cancer nanomedicines and their future applications within the context of personalized and precision therapies and diagnostics are discussed.

Publication metadata

Author(s): Khoshtinat Nikkhoi S, Rahbarizadeh F, Ahmadvand D, Moghimi SM

Publication type: Article

Publication status: Published

Journal: European Journal of Pharmaceutical Sciences

Year: 2018

Volume: 122

Pages: 42-50

Print publication date: 15/09/2018

Online publication date: 19/06/2018

Acceptance date: 18/06/2018

ISSN (print): 0928-0987

ISSN (electronic): 1879-0720

Publisher: Elsevier BV


DOI: 10.1016/j.ejps.2018.06.019


Altmetrics provided by Altmetric